JP6913026B2 - インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体 - Google Patents

インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体 Download PDF

Info

Publication number
JP6913026B2
JP6913026B2 JP2017553885A JP2017553885A JP6913026B2 JP 6913026 B2 JP6913026 B2 JP 6913026B2 JP 2017553885 A JP2017553885 A JP 2017553885A JP 2017553885 A JP2017553885 A JP 2017553885A JP 6913026 B2 JP6913026 B2 JP 6913026B2
Authority
JP
Japan
Prior art keywords
ser
isolated
binder
seq
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017553885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512157A5 (https=
JP2018512157A (ja
Inventor
バウワーズ、ピーター
ジョン マックナイト、アンドリュー
ジョン マックナイト、アンドリュー
ジェイ． キング、デイヴィッド
ジェイ． キング、デイヴィッド
ロンデイ、マルコ
Original Assignee
アナプティスバイオ インコーポレイティッド
アナプティスバイオ インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アナプティスバイオ インコーポレイティッド, アナプティスバイオ インコーポレイティッド filed Critical アナプティスバイオ インコーポレイティッド
Publication of JP2018512157A publication Critical patent/JP2018512157A/ja
Publication of JP2018512157A5 publication Critical patent/JP2018512157A5/ja
Priority to JP2021069306A priority Critical patent/JP7212098B2/ja
Application granted granted Critical
Publication of JP6913026B2 publication Critical patent/JP6913026B2/ja
Priority to JP2023003385A priority patent/JP7721585B2/ja
Priority to JP2025127775A priority patent/JP2025163120A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017553885A 2015-04-15 2016-04-15 インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体 Active JP6913026B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021069306A JP7212098B2 (ja) 2015-04-15 2021-04-15 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
JP2023003385A JP7721585B2 (ja) 2015-04-15 2023-01-12 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
JP2025127775A JP2025163120A (ja) 2015-04-15 2025-07-30 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562147824P 2015-04-15 2015-04-15
US62/147,824 2015-04-15
PCT/US2016/027676 WO2016168542A1 (en) 2015-04-15 2016-04-15 Antibodies directed against interleukin 36 receptor (il-36r)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021069306A Division JP7212098B2 (ja) 2015-04-15 2021-04-15 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体

Publications (3)

Publication Number Publication Date
JP2018512157A JP2018512157A (ja) 2018-05-17
JP2018512157A5 JP2018512157A5 (https=) 2019-05-23
JP6913026B2 true JP6913026B2 (ja) 2021-08-04

Family

ID=57126337

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017553885A Active JP6913026B2 (ja) 2015-04-15 2016-04-15 インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体
JP2021069306A Active JP7212098B2 (ja) 2015-04-15 2021-04-15 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
JP2023003385A Active JP7721585B2 (ja) 2015-04-15 2023-01-12 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
JP2025127775A Pending JP2025163120A (ja) 2015-04-15 2025-07-30 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021069306A Active JP7212098B2 (ja) 2015-04-15 2021-04-15 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
JP2023003385A Active JP7721585B2 (ja) 2015-04-15 2023-01-12 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
JP2025127775A Pending JP2025163120A (ja) 2015-04-15 2025-07-30 インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体

Country Status (14)

Country Link
US (4) US10526410B2 (https=)
EP (2) EP3283110B1 (https=)
JP (4) JP6913026B2 (https=)
KR (1) KR102666920B1 (https=)
CN (2) CN115925932A (https=)
AU (1) AU2016248208B2 (https=)
CA (1) CA2982555A1 (https=)
DK (1) DK3283110T3 (https=)
ES (1) ES2914243T3 (https=)
MX (2) MX2017013080A (https=)
PL (1) PL3283110T3 (https=)
RU (1) RU2745898C2 (https=)
SG (1) SG11201708061TA (https=)
WO (1) WO2016168542A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3536710T1 (sl) 2011-11-16 2026-04-30 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
CN115925932A (zh) * 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
JP2020512344A (ja) * 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
EP3400962A1 (en) * 2017-05-09 2018-11-14 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Inhibitors of il-38 for use in treating and/or preventing cancer in a subject
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
JP2021517577A (ja) * 2018-03-14 2021-07-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性腸疾患の処置のための抗ｉｌ−３６ｒ抗体の使用
BR112020016738A2 (pt) * 2018-03-14 2020-12-15 Boehringer Ingelheim International Gmbh Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada
HRP20240999T1 (hr) 2018-07-16 2024-10-25 Regeneron Pharmaceuticals, Inc. Glodavački modeli bolesti ditra i njihova upotreba
AU2019306217B2 (en) * 2018-07-16 2024-01-25 Regeneron Pharmaceuticals, Inc. Anti-IL36R antibodies
CN110818796B (zh) * 2018-08-09 2022-11-08 东莞市朋志生物科技有限公司 一种抗人ca153蛋白的重组抗体
CA3120474A1 (en) 2018-12-21 2020-06-25 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
TW202037604A (zh) * 2018-12-27 2020-10-16 德商百靈佳殷格翰國際股份有限公司 治療掌蹠膿疱症之抗il-36r抗體
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
IL286100B2 (en) * 2019-03-08 2024-12-01 Boehringer Ingelheim Int Anti-il-36r antibody formulations
CA3147020A1 (en) * 2019-08-07 2021-02-11 Joe G.N. Garcia Anti-nampt antibodies and uses thereof
JP7811772B2 (ja) * 2019-12-05 2026-02-06 学校法人東京薬科大学 筋組織の減少を抑制するための組成物
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
BR112022026999A2 (pt) * 2020-07-17 2023-01-24 Boehringer Ingelheim Int Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
EP4188441A1 (en) 2020-07-30 2023-06-07 AnaptysBio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
CA3209006A1 (en) * 2021-03-04 2022-09-09 Boehringer Ingelheim International Gmbh Methods for the treatment of gpp
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
JP2024518536A (ja) * 2021-05-12 2024-05-01 アナプティスバイオ インコーポレイティッド 抗体組成物
EP4370550A1 (en) 2021-07-12 2024-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
TW202323293A (zh) * 2021-10-29 2023-06-16 新加坡商創響私人有限公司 新型抗ｉｌ－３６ｒ抗體
CN115724975A (zh) 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6843987B2 (en) 2000-02-02 2005-01-18 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2008033333A2 (en) 2006-09-08 2008-03-20 Amgen Inc. Il-1 family variants
US20090075378A1 (en) 2007-02-20 2009-03-19 Anaptysbio, Inc. Somatic hypermutation systems
KR20110048536A (ko) 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
SI3536710T1 (sl) * 2011-11-16 2026-04-30 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
WO2013098420A1 (en) 2011-12-28 2013-07-04 Immunoqure Ag Method of isolating human antibodies
WO2014165115A1 (en) * 2013-03-12 2014-10-09 Decimmune Therapeutics, Inc. Humanized anti-n2 antibodies
CN115925932A (zh) * 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
JP2021517577A (ja) 2018-03-14 2021-07-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性腸疾患の処置のための抗ｉｌ−３６ｒ抗体の使用
BR112020016738A2 (pt) 2018-03-14 2020-12-15 Boehringer Ingelheim International Gmbh Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada
AU2019306217B2 (en) 2018-07-16 2024-01-25 Regeneron Pharmaceuticals, Inc. Anti-IL36R antibodies
CA3120474A1 (en) 2018-12-21 2020-06-25 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
TW202037604A (zh) 2018-12-27 2020-10-16 德商百靈佳殷格翰國際股份有限公司 治療掌蹠膿疱症之抗il-36r抗體
IL286100B2 (en) 2019-03-08 2024-12-01 Boehringer Ingelheim Int Anti-il-36r antibody formulations
CN113316587B (zh) 2019-05-20 2024-03-26 南通壹宸生物医药科技有限公司 一种双特异性分子及其制备与用途

Also Published As

Publication number Publication date
US20200087408A1 (en) 2020-03-19
EP3283110A1 (en) 2018-02-21
JP2023040236A (ja) 2023-03-22
CN115925932A (zh) 2023-04-07
MX2023001791A (es) 2023-03-10
US10526410B2 (en) 2020-01-07
JP7721585B2 (ja) 2025-08-12
EP3283110A4 (en) 2019-02-27
NZ736535A (en) 2024-08-30
RU2745898C2 (ru) 2021-04-02
EP3283110B1 (en) 2022-04-20
HK1250941A1 (en) 2019-01-18
KR102666920B1 (ko) 2024-05-20
JP7212098B2 (ja) 2023-01-24
CN107847590B (zh) 2022-07-26
AU2016248208A1 (en) 2017-11-09
US20210388095A1 (en) 2021-12-16
US12391761B2 (en) 2025-08-19
MX2017013080A (es) 2018-02-09
US20260022181A1 (en) 2026-01-22
RU2017139481A (ru) 2019-05-15
CA2982555A1 (en) 2016-10-20
HK1252009A1 (zh) 2019-05-10
EP4176900A1 (en) 2023-05-10
US20180094065A1 (en) 2018-04-05
US11130814B2 (en) 2021-09-28
SG11201708061TA (en) 2017-10-30
AU2016248208B2 (en) 2022-03-24
KR20180002687A (ko) 2018-01-08
ES2914243T3 (es) 2022-06-08
WO2016168542A1 (en) 2016-10-20
JP2021118710A (ja) 2021-08-12
CN107847590A (zh) 2018-03-27
BR112017022086A2 (pt) 2018-07-03
PL3283110T3 (pl) 2022-06-27
RU2017139481A3 (https=) 2019-09-19
DK3283110T3 (da) 2022-05-23
JP2025163120A (ja) 2025-10-28
JP2018512157A (ja) 2018-05-17

Similar Documents

Publication Publication Date Title
JP7721585B2 (ja) インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
US20240294631A1 (en) Antibodies directed against interleukin-33 (il-33)
HK40086847A (en) Antibodies directed against interleukin 36 receptor (il-36r)
HK1250941B (en) Antibodies directed against interleukin 36 receptor (il-36r)
BR112017022086B1 (pt) Anticorpo isolado de receptor de interleucina-36 ou fragmento de ligação ao antígeno do mesmo, composição seus usos
HK1252009B (en) Antibodies directed against interleukin 36 receptor (il-36r)
HK1231082A1 (en) Antibodies directed against interleukin-33 (il-33)
HK1231082B (en) Antibodies directed against interleukin-33 (il-33)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171122

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20171122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190415

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200720

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210415

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210415

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210422

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210615

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210709

R150 Certificate of patent or registration of utility model

Ref document number: 6913026

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250